Skip to content

RNTX RNTX License — Cost of Goods Sold

Similar metrics at other companies

Eton Pharmaceuticals, Inc. logo
ETONLicense — Cost of Goods Sold
$0-100%
eGain logo
EGANLicense — Cost of Goods Sold
$4.53M-1.3%
Nathan's Famous logo
NATHProduct Licensing — Cost of Goods Sold
$0
Vertex, Inc. logo
VERXLicense And Service — Cost of Goods Sold
$51.18M+15.7%
PLB
PLBYLicensing — Cost of Product and Service Sold
$1.49M+150%
PVH logo
PVHLicensing Segment — Cost of goods sold
$0

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+177%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's license — cost of goods sold.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's license — cost of goods sold?
RNTX (RNTX) reported license — cost of goods sold of $0 in Q1 2026.
What is the long-term trend for RNTX's license — cost of goods sold?
Over 2 years (2021 to 2025), RNTX's license — cost of goods sold has grown at a -58.5% compound annual growth rate (CAGR), from $145K to $25K.
What does license — cost of goods sold mean?
This metric represents the direct costs incurred by the company to generate revenue specifically from its licensing activities. It encompasses expenses directly attributable to the delivery of licensed intellectual property or related services, excluding general operating expenses. Monitoring this figure helps investors assess the profitability and operational efficiency of the company's licensing business model.